drugset / Trial / NCT00050843

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

NCT00050843

Phase 3 Completed 220 enrolled Celgene Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of the study is to determine the efficacy of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes (MDS).

Timeline

Start
2001-08
Primary completion
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified